0

Effects of the Protein Tyrosine Kinase Inhibitor, SU5614, on Leukemic and Normal Stem Cells

Natalia Arseni, Farid Ahmed, Wolfgang Hiddemann, Christian Buske, Michaela Feuring-Buske

Haematologica. 2005 Nov;90(11):1577-8.

PMID: 16266907

Abstract:

FLT3 activating mutations are the most frequent single genetic abnormality in patients with acute myeloid leukemia. Thus targeting the FLT3 activated kinase is a promising treatment approach. We wanted to test whether the protein tyrosine kinase inhibitor SU5614 selectively eliminates leukemic stem cells while sparing their normal counterparts.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1055412479 SU5614 SU5614 1055412-47-9 Price
qrcode